ARCHIVES

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

DCT Board Sends Letter Opposing Bill Requiring Research On RU 486

November 13, 1992

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

New Criteria For Comprehensive center Status finalized

November 17, 1989

Emory Stops Patient Accrual After Discovering Problems In Management

June 26, 2009

P01 Reviewers Asked To Look Closely At Number Of Projects

October 2, 1992

Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI

March 22, 2013